Lineage Cell Therapeutics (LCTX) Misses Q4 EPS by 11c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of ($0.15), $0.11 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Robinhood closes $2.2B convertible notes offering at 0% interest
• Berenberg Downgrades Berkeley Group Holdings Plc. (BKG:LN) (BKGFF) to Hold